Journal: Frontiers in Cellular and Infection Microbiology

Article Title: A Novel Chimeric Endolysin with Antibacterial Activity against Methicillin-Resistant Staphylococcus aureus

doi: 10.3389/fcimb.2017.00290

Figure Lengend Snippet: Bacterial species evaluated for sensitivity to CHAP-amidase.

Article Snippet: Escherichia coli , NDM 1 , Multi-drug resistant (ATCC BAA-2452) , Pakistan.

Techniques: Isolation

Journal: The Journal of Clinical Investigation

Article Title: Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents

doi: 10.1172/JCI94258

Figure Lengend Snippet: (A) Comparative therapeutic efficacy of VLB, DAVLBH, Z-GP-DAVLBH, and Boc-AP-DAVLBH in MDA-MB-231 xenografts. Mice bearing MDA-MB-231 xenografts received an i.v. injection of saline (containing 1% DMSO), VLB, DAVLBH, Z-GP-DAVLBH, or Boc-AP-DAVLBH once every other day for 14 days. Each curve represents the growth of a single tumor in an individual mouse. The dotted vertical lines denote the final day of dosing. (B) Detection of the anticancer spectrum of Z-GP-DAVLBH. Mice bearing HepG2 xenografts (n = 5), A549 xenografts (n = 5), HeLa xenografts (n = 5), CNE-2 xenografts (n = 6), invasive ductal carcinoma patient-derived xenografts (PDX, n = 5), and hepatocellular carcinoma PDX (n = 5) received an i.v. injection of Z-GP-DAVLBH (2.0 μmol/kg) once every other day for 12 or 14 days. Mice in the vehicle group received saline (containing 1% DMSO) only. (C and D) The antitumor effects of Z-GP-DAVLBH in the large MDA-MB-231 tumor experiment. Mice bearing MDA-MB-231 xenografts received 2.0 μmol/kg i.v. injection of Z-GP-DAVLBH or saline containing 1% DMSO once every other day for 16 or 32 days, until the tumor volume reached approximately (C) 750 mm3 (n = 5) or (D) 2,500 mm3 (n = 5). For B–D, the tumor volume (left) and the tumor weight (right) are shown. The results are expressed as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 versus the vehicle group based on a 2-tailed unpaired t test.

Article Snippet: The human embryonic kidney cell line HEK 293T, the mouse embryo fibroblast cell line BALB/3T3, the human breast adenocarcinoma cell line MDA-MB-231, the human hepatocellular carcinoma cell line HepG2, the human cervix adenocarcinoma cell line HeLa, and the human lung carcinoma cell line A549 were obtained from ATCC, and the human nasopharyngeal carcinoma cell line CNE-2 was a gift from Jian Hong (Southern Medical University).

Techniques: Drug discovery, Injection, Saline, Derivative Assay

Journal: American Journal of Cancer Research

Article Title: Activation of the IL-17 signalling pathway by the CXCL17-GPR35 axis affects drug resistance and colorectal cancer tumorigenesis

doi:

Figure Lengend Snippet: Chemokine CXCL17 and its receptor GPR35 exhibit higher levels in CRC drug-resistant tissues and cells. A. Differential gene volcano plot between OXA-sensitive and OXA-resistant groups in CRC tissues; B. Box plot of CXCL17 expression in OXA-sensitive and OXA-resistant tumor tissues; C. Western-blot detection of CXCL17 and GPR35 protein expression levels in FHC and HCT15 cells; D. RT-qPCR detection of mRNA expression of CXCL17 and GPR35. **P < 0.01, compared with the FHC group.

Article Snippet: Drug-resistant human colorectal cancer cells (HCT15) were cultured in RPMI 1640 medium supplemented with 10% foetal bovine serum, 1% penicillin and streptomycin, and 500 ng/ml taxol (a microtubule-stabilising drug used to treat cancer) (Med Chem Express, Monmouth Junction, NJ, USA).

Techniques: Expressing, Western Blot, Quantitative RT-PCR

Journal: American Journal of Cancer Research

Article Title: Activation of the IL-17 signalling pathway by the CXCL17-GPR35 axis affects drug resistance and colorectal cancer tumorigenesis

doi:

Figure Lengend Snippet: CXCL17 plays a critical role in proliferation and drug-resistance of HCT15 cells. A, B. CCK-8 assay was performed to detect cell viability after the treatment with CXCL17 silence or different concentrations of taxol; C. Wound-healing assay for cell migration ability of HCT15 cells upon siNC or si-CXCL17 transfection; D. Transwell assay was applied to analyze cell invasion ability; E. Cell cycle was detected by flow cytometry; F. Cell apoptosis was detected by flow cytometry. Scale bar was 50 μm. Compared with siNC group, *P < 0.05; **P < 0.01.

Article Snippet: Drug-resistant human colorectal cancer cells (HCT15) were cultured in RPMI 1640 medium supplemented with 10% foetal bovine serum, 1% penicillin and streptomycin, and 500 ng/ml taxol (a microtubule-stabilising drug used to treat cancer) (Med Chem Express, Monmouth Junction, NJ, USA).

Techniques: CCK-8 Assay, Wound Healing Assay, Migration, Transfection, Transwell Assay, Flow Cytometry

Journal: American Journal of Cancer Research

Article Title: Activation of the IL-17 signalling pathway by the CXCL17-GPR35 axis affects drug resistance and colorectal cancer tumorigenesis

doi:

Figure Lengend Snippet: IL-17 signaling pathway is involved in tumorigenesis and drug resistance of HCT15 cells. A. CCK-8 assay was performed to detect cell viability of HCT15 cells with or without CXCL17 silence upon IL-17A supplementation; B. CCK-8 assay for cell resistance was applied to detect the cell viability of HCT15 cells with or without CXCL17 silence which treated with different concentrations of taxol; C. Wound-healing assay was used to evaluate cell migration ability of HCT15 cells treated with IL-17A followed by siNC or si-CXCL17 transfection; D. Transwell assay was applied to analyze cell invasion ability of HCT15 treated with IL-17A followed by siNC or si-CXCL17 transfection; E. Flow cytometry was used to detect the cell cycle of HCT15 cells treated with IL-17A followed by siNC or si-CXCL17 transfection; F. Flow cytometry was used to detect the cell apoptosis of HCT15 cells treated with IL-17A followed by siNC or si-CXCL17 transfection. Scale bar was 50 μm. Compared with the siNC group, **P < 0.01; compared with the si-CXCL17 group, #P < 0.05; ##P < 0.01.

Article Snippet: Drug-resistant human colorectal cancer cells (HCT15) were cultured in RPMI 1640 medium supplemented with 10% foetal bovine serum, 1% penicillin and streptomycin, and 500 ng/ml taxol (a microtubule-stabilising drug used to treat cancer) (Med Chem Express, Monmouth Junction, NJ, USA).

Techniques: CCK-8 Assay, Wound Healing Assay, Migration, Transfection, Transwell Assay, Flow Cytometry